The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Chimeric antigen receptor (CAR) technology has revolutionized cancer treatment, particularly in malignant hematological tumors. Currently, the BCMA-targeted second-generation CAR-T cells have showed impressive efficacy in the treatment of refractory/relapsed multiple myeloma (R/R MM), but up to 50%...

Full description

Bibliographic Details
Main Authors: Deming Duan, Keke Wang, Cheng Wei, Dudu Feng, Yonghua Liu, Qingyan He, Xing Xu, Chunling Wang, Shuping Zhao, Leili Lv, Jing Long, Danni Lin, Ai Zhao, Bingmu Fang, Jinhong Jiang, Shixing Tang, Jimin Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Immunology
Subjects:
multiple myeloma
CAR-T
BCMA
IL-7
CCL19
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.609421/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.609421/full

Similar Items